<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519285</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6546</org_study_id>
    <secondary_id>2006-004756-20</secondary_id>
    <nct_id>NCT00519285</nct_id>
  </id_info>
  <brief_title>Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer</brief_title>
  <acronym>VENICE</acronym>
  <official_title>A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective was to demonstrate overall survival improvement with aflibercept compared
      to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent
      prostate cancer (MAIPC).

      The secondary objectives were:

        -  To assess the efficacy of aflibercept compared to placebo on other parameters such
           prostate-specific antigen (PSA) level, cancer related pain, progression free survival
           (PFS), tumor-based and skeletal events and health-related quality of life (HRQL);

        -  To assess the overall safety in both treatment arms;

        -  To determine the pharmacokinetics of intravenous (IV) aflibercept in this population;

        -  to determine immunogenicity of IV aflibercept.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted in 3-week treatment cycles until progressive disease, unacceptable
      toxicity, or participant's refusal of further study treatment. After disease progression,
      participants were to be followed every 3 months until death or the study cutoff date,
      whichever came first.

      The study cut-off date was event-driven and was defined as the date when 873 deaths had
      occurred.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival Time</measure>
    <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
    <description>Overall survival (OS) time was measured as the time from date of randomization to the date of death due to any cause.
The median OS time and its 95.6% confidence interval were estimated using the Kaplan-Meier method. In the absence of confirmation of death, the participant was censored at the last date he/she was known to be alive or the study cut-off date (when 873 deaths have occurred), whichever was earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen Response Rate</measure>
    <time_frame>Before randomization (baseline) then every 3 weeks up to PSA progression (≥25% increase) or the cut-off date, whichever occurred first</time_frame>
    <description>Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Skeletal Related Events</measure>
    <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
    <description>Skeletal Related Events (SRE) included pathological fractures and/or spinal cord compression, need for bone irradiation, including radioisotopes or bone surgery, change in antineoplastic therapy to treat bone pain.
Time to SRE was defined as the time from the date of randomization to the date of occurence of the first event defining a SRE or death due to any cause, whichever occurred first.
The median time to SRE and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of SRE, the participant was censored at the last date he/she was known to be alive or the study cut-off date, whichever was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Time</measure>
    <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
    <description>Disease progression was defined as a composite of: Radiological tumor progression (≥20% increase in target lesions, or appearance of at least 2 new bone lesions); PSA progression (≥25% increase in PSA level confirmed 3 weeks later); Pain progression (increase in pain intensity or in analgesic consumption for cancer related pain confirmed 3 weeks later); Radiotherapy for cancer related symptoms; Occurence of Skeletal related events (SRE).
Progression Free survival (PFS) time was measured as the time from the date of randomization up to the date of occurrence of the first event defining a disease progression or death due to any cause, whichever occurred first.
The median PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of disease progression, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response Rate in Participants With Measurable Disease</measure>
    <time_frame>Before randomization (baseline) then every 3 months up to tumor progression (≥25% increase) or the cut-off date, whichever occurred first</time_frame>
    <description>Tumor response was defined as either a Complete Response (disappearance of all target lesions) or a Partial Response (≥30% decrease from baseline in target lesions) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST)version 1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen Progression-free Survival Time</measure>
    <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
    <description>Prostate specific antigen (PSA) progression was defined as ≥25% increase in PSA level confirmed 3 weeks later, above the nadir in participants who had achieved a PSA response, or above the baseline in participants who hadn't achieved a PSA response.
PSA progression-free survival (PFS) time was defined as the time from the date of randomization up to the date of the first documented PSA progression or death due to any cause, whichever occurred first.
The median PSA-PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of PSA progression or death, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Progression-free Survival Time</measure>
    <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
    <description>Pain progression was defined as either ≥1-point increase in Present Pain Intensity (PPI) score or ≥25% increase in Analgesics Score (AS) confirmed at least 3 weeks later, or requirement for palliative radiotherapy. PPI scale is a self-report 0-5 scale to assess pain intensity - a score 0 reflects no pain, a score 5 reflects excruciating pain. AS is a scoring method to assess analgesics consumption. Each analgesic is scored 1 or 4 depending on the analgesic type and dose. AS is the sum of the analgesic scores.
Pain progression-free survival (PFS) time was measured as the time from the date of randomization up to the date of first pain progression or death due to any cause, whichever occurred first.
The median pain-PFS and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of event, the participant was censored at the the date of last assessment without evidence of pain progression or the study cut-off date, whichever was earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Response Rate</measure>
    <time_frame>Before randomization (baseline) then every 3 weeks up to pain progression or the cut-off date, whichever occurred first</time_frame>
    <description>Pain response was defined as either a ≥2-point decrease from baseline in Present Pain Intensity (PPI) score without increase in Analgesics Score (AS), or a ≥50% decrease from baseline in AS without increase in the PPI score confirmed at least 3 weeks later. Increases in PPI or AS during the first 12 weeks were ignored in determining pain response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life</measure>
    <time_frame>Before randomization (baseline) then every 3 weeks until disease progression or administration of further antitumor therapy, whichever came first</time_frame>
    <description>Functional Assessment of Cancer Therapy-Prostate (FACT-P) is a 39-item participant questionnaire that measures the concerns of patients with prostate cancer. It consists of 5 subscales assessing physical well-being, social/family well-being, emotional well-being, functional well-being, and prostate-specific concerns.
FACT-P total score is the sum of the 5 subscores. It ranges from 0 to 156 with higher score indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety</measure>
    <time_frame>From first dose of study treatment (aflibercept/placebo or docetaxel whichever came first) to last dose of study treatment (aflibercept/placebo or docetaxel whichever came last) + 30 days</time_frame>
    <description>Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome or illness observed by the investigator or reported by the participant during the study.
AE were collected at regular intervals throughout the study then graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.3.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept</measure>
    <time_frame>Pre-dose of cycle 1 (baseline), pre-dose of each every other cycle, then 30 and 90 days after the last administration of the study drug</time_frame>
    <description>Serum for detection of anti-drug antibodies (ADA) was collected in patients treated in selected centers only. Samples were analyzed using a titer-based, bridging immunoassay developed and validated to detect ADAs in human serum.
Samples with positive antibody levels were further analyzed using a validated, non-quantitative ligand binding assay to detect neutralizing antibodies Ab).
A participant was considered to have positive antibody levels if antibodies were detected above the quantification limits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1224</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>25 mg/ml solution
6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>AVE0005</other_name>
    <other_name>ZALTRAP®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for aflibercept)</intervention_name>
    <description>Sterile aqueous buffered solution identical to aflibercept
1-hour IV on Day 1 of each 3-Week cycle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Marketed formulation
75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>Taxotere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone or Prednisolone</intervention_name>
    <description>Marketed formulation
5 mg twice daily PO from day 1 continuously</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- or cytologically-confirmed prostate adenocarcinoma;

          -  Metastatic disease;

          -  Progressive disease while receiving hormonal therapy or after surgical castration;

          -  Effective castration.

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except
             adjuvant/neoadjuvant treatment completed &gt;3 years ago;

          -  Prior treatment with Vascular Endothelial Growth Factor (VEGF) inhibitors or VEGF
             receptor inhibitors;

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt;2.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Providencia Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>City of Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4.</citation>
    <PMID>23742877</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2007</study_first_submitted>
  <study_first_submitted_qc>August 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2007</study_first_posted>
  <results_first_submitted>April 25, 2013</results_first_submitted>
  <results_first_submitted_qc>August 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2013</results_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between August 2007 and February 2010, a total of 1548 patients gave informed consent for this study.</recruitment_details>
      <pre_assignment_details>Amongst these patients, a total of 324 were screening failures (primarily due to non-compliance with exclusion criteria) and did not get randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
        </group>
        <group group_id="P2">
          <title>Aflibercept</title>
          <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="612">Randomized</participants>
                <participants group_id="P2" count="612">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="604">Received at least part of one dose of placebo</participants>
                <participants group_id="P2" count="605">Received at least part of one dose of aflibercept</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Still Treated at Cut-off Date</title>
              <participants_list>
                <participants group_id="P1" count="1">The cut-off date for analysis was defined as 07 February 2012, date at which 873 deaths has occurred</participants>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants were treated until progressive disease, unacceptable toxicity, or refusal of treatment</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="612"/>
                <participants group_id="P2" count="612"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="266"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="334"/>
                <participants group_id="P2" count="186"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant's request</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason unspecified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment ongoing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
        </group>
        <group group_id="B2">
          <title>Aflibercept</title>
          <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="612"/>
            <count group_id="B2" value="612"/>
            <count group_id="B3" value="1224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="8.0"/>
                    <measurement group_id="B2" value="67.9" spread="7.8"/>
                    <measurement group_id="B3" value="67.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="612"/>
                    <measurement group_id="B2" value="612"/>
                    <measurement group_id="B3" value="1224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian/White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="552"/>
                    <measurement group_id="B2" value="560"/>
                    <measurement group_id="B3" value="1112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Western Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other region</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area (BSA)</title>
          <units>m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="0.2"/>
                    <measurement group_id="B2" value="2.0" spread="0.2"/>
                    <measurement group_id="B3" value="2.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Co-operative Group (ECOG) performance status</title>
          <description>ECOG performance status:
0 = Fully active, able to carry on all pre-disease performance without restriction
1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
2 = Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival Time</title>
        <description>Overall survival (OS) time was measured as the time from date of randomization to the date of death due to any cause.
The median OS time and its 95.6% confidence interval were estimated using the Kaplan-Meier method. In the absence of confirmation of death, the participant was censored at the last date he/she was known to be alive or the study cut-off date (when 873 deaths have occurred), whichever was earlier.</description>
        <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
        <population>The analysis was performed on the Intent-to-treat (ITT) population (i.e all randomized participants according to the treatment assigned regardless of the drug actually received).
At the cut-off date, 873 deaths had occurred, 445 in the Placebo group and 428 in the Aflibercept group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time</title>
          <description>Overall survival (OS) time was measured as the time from date of randomization to the date of death due to any cause.
The median OS time and its 95.6% confidence interval were estimated using the Kaplan-Meier method. In the absence of confirmation of death, the participant was censored at the last date he/she was known to be alive or the study cut-off date (when 873 deaths have occurred), whichever was earlier.</description>
          <population>The analysis was performed on the Intent-to-treat (ITT) population (i.e all randomized participants according to the treatment assigned regardless of the drug actually received).
At the cut-off date, 873 deaths had occurred, 445 in the Placebo group and 428 in the Aflibercept group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.22" lower_limit="19.614" upper_limit="23.754"/>
                    <measurement group_id="O2" value="22.14" lower_limit="20.304" upper_limit="24.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between aflibercept and placebo
The study was designed to provide 90% power to detect a 1.25-fold increase in median survival with aflibercept compared to placebo at a overall one-sided significance level of 0.025 with 873 deaths.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3802</p_value>
            <p_value_desc>A priori threshold for statistical significance was set to 0.044 using the O'Brien-Fleming alpha spending function to account for two interim analyses.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified on ECOG Performance Status</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.942</param_value>
            <ci_percent>95.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.822</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Hazard ratio (HR) aflibercept versus placebo estimated from a Cox proportional hazard model stratified on ECOG Performance Status</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Specific Antigen Response Rate</title>
        <description>Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response.</description>
        <time_frame>Before randomization (baseline) then every 3 weeks up to PSA progression (≥25% increase) or the cut-off date, whichever occurred first</time_frame>
        <population>The analysis was performed on the ITT population evaluable for PSA response (i.e. with a baseline PSA ≥10 ng/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen Response Rate</title>
          <description>Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response.</description>
          <population>The analysis was performed on the ITT population evaluable for PSA response (i.e. with a baseline PSA ≥10 ng/mL).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="559"/>
                <count group_id="O2" value="560"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="59.5" upper_limit="67.5"/>
                    <measurement group_id="O2" value="68.6" lower_limit="64.7" upper_limit="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Skeletal Related Events</title>
        <description>Skeletal Related Events (SRE) included pathological fractures and/or spinal cord compression, need for bone irradiation, including radioisotopes or bone surgery, change in antineoplastic therapy to treat bone pain.
Time to SRE was defined as the time from the date of randomization to the date of occurence of the first event defining a SRE or death due to any cause, whichever occurred first.
The median time to SRE and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of SRE, the participant was censored at the last date he/she was known to be alive or the study cut-off date, whichever was earlier.</description>
        <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
        <population>The analysis was performed on the ITT population.
At the cut-off date, SRE or death had occurred in 1013 participants, 516 in the Placebo group and 497 in the Aflibercept group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Skeletal Related Events</title>
          <description>Skeletal Related Events (SRE) included pathological fractures and/or spinal cord compression, need for bone irradiation, including radioisotopes or bone surgery, change in antineoplastic therapy to treat bone pain.
Time to SRE was defined as the time from the date of randomization to the date of occurence of the first event defining a SRE or death due to any cause, whichever occurred first.
The median time to SRE and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of SRE, the participant was censored at the last date he/she was known to be alive or the study cut-off date, whichever was earlier.</description>
          <population>The analysis was performed on the ITT population.
At the cut-off date, SRE or death had occurred in 1013 participants, 516 in the Placebo group and 497 in the Aflibercept group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.98" lower_limit="13.733" upper_limit="16.427"/>
                    <measurement group_id="O2" value="15.31" lower_limit="14.127" upper_limit="16.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival Time</title>
        <description>Disease progression was defined as a composite of: Radiological tumor progression (≥20% increase in target lesions, or appearance of at least 2 new bone lesions); PSA progression (≥25% increase in PSA level confirmed 3 weeks later); Pain progression (increase in pain intensity or in analgesic consumption for cancer related pain confirmed 3 weeks later); Radiotherapy for cancer related symptoms; Occurence of Skeletal related events (SRE).
Progression Free survival (PFS) time was measured as the time from the date of randomization up to the date of occurrence of the first event defining a disease progression or death due to any cause, whichever occurred first.
The median PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of disease progression, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.</description>
        <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
        <population>The analysis was performed on the ITT population.
At the cut-off date, disease progression or death had occurred in 1184 participants, 592 in each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Time</title>
          <description>Disease progression was defined as a composite of: Radiological tumor progression (≥20% increase in target lesions, or appearance of at least 2 new bone lesions); PSA progression (≥25% increase in PSA level confirmed 3 weeks later); Pain progression (increase in pain intensity or in analgesic consumption for cancer related pain confirmed 3 weeks later); Radiotherapy for cancer related symptoms; Occurence of Skeletal related events (SRE).
Progression Free survival (PFS) time was measured as the time from the date of randomization up to the date of occurrence of the first event defining a disease progression or death due to any cause, whichever occurred first.
The median PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of disease progression, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.</description>
          <population>The analysis was performed on the ITT population.
At the cut-off date, disease progression or death had occurred in 1184 participants, 592 in each treatment group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" lower_limit="5.585" upper_limit="6.899"/>
                    <measurement group_id="O2" value="6.90" lower_limit="6.209" upper_limit="7.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Response Rate in Participants With Measurable Disease</title>
        <description>Tumor response was defined as either a Complete Response (disappearance of all target lesions) or a Partial Response (≥30% decrease from baseline in target lesions) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST)version 1.0.</description>
        <time_frame>Before randomization (baseline) then every 3 months up to tumor progression (≥25% increase) or the cut-off date, whichever occurred first</time_frame>
        <population>The analysis was performed on the ITT population evaluable for tumor response (i.e. received at least one dose of study drugs (aflibercept/placebo or docetaxel), had no important deviations to protocol and was evaluable for response as per RECIST version 1.0).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response Rate in Participants With Measurable Disease</title>
          <description>Tumor response was defined as either a Complete Response (disappearance of all target lesions) or a Partial Response (≥30% decrease from baseline in target lesions) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST)version 1.0.</description>
          <population>The analysis was performed on the ITT population evaluable for tumor response (i.e. received at least one dose of study drugs (aflibercept/placebo or docetaxel), had no important deviations to protocol and was evaluable for response as per RECIST version 1.0).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="23.2" upper_limit="33.1"/>
                    <measurement group_id="O2" value="38.7" lower_limit="33.4" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Specific Antigen Progression-free Survival Time</title>
        <description>Prostate specific antigen (PSA) progression was defined as ≥25% increase in PSA level confirmed 3 weeks later, above the nadir in participants who had achieved a PSA response, or above the baseline in participants who hadn't achieved a PSA response.
PSA progression-free survival (PFS) time was defined as the time from the date of randomization up to the date of the first documented PSA progression or death due to any cause, whichever occurred first.
The median PSA-PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of PSA progression or death, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.</description>
        <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
        <population>The analysis was performed in the ITT population evaluable for PSA progression (i.e. with an evaluable baseline PSA).
At the cut-off date, PSA progression or death had occurred in 1138 participants, 571 in the Placebo group and 567 in the Aflibercept group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen Progression-free Survival Time</title>
          <description>Prostate specific antigen (PSA) progression was defined as ≥25% increase in PSA level confirmed 3 weeks later, above the nadir in participants who had achieved a PSA response, or above the baseline in participants who hadn't achieved a PSA response.
PSA progression-free survival (PFS) time was defined as the time from the date of randomization up to the date of the first documented PSA progression or death due to any cause, whichever occurred first.
The median PSA-PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of PSA progression or death, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.</description>
          <population>The analysis was performed in the ITT population evaluable for PSA progression (i.e. with an evaluable baseline PSA).
At the cut-off date, PSA progression or death had occurred in 1138 participants, 571 in the Placebo group and 567 in the Aflibercept group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.11" lower_limit="7.622" upper_limit="8.575"/>
                    <measurement group_id="O2" value="8.25" lower_limit="7.819" upper_limit="8.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Progression-free Survival Time</title>
        <description>Pain progression was defined as either ≥1-point increase in Present Pain Intensity (PPI) score or ≥25% increase in Analgesics Score (AS) confirmed at least 3 weeks later, or requirement for palliative radiotherapy. PPI scale is a self-report 0-5 scale to assess pain intensity - a score 0 reflects no pain, a score 5 reflects excruciating pain. AS is a scoring method to assess analgesics consumption. Each analgesic is scored 1 or 4 depending on the analgesic type and dose. AS is the sum of the analgesic scores.
Pain progression-free survival (PFS) time was measured as the time from the date of randomization up to the date of first pain progression or death due to any cause, whichever occurred first.
The median pain-PFS and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of event, the participant was censored at the the date of last assessment without evidence of pain progression or the study cut-off date, whichever was earlier.</description>
        <time_frame>From randomization up to the cut-off date (median follow-up of 35.4 months)</time_frame>
        <population>The analysis was performed on the ITT population evaluable for pain progression (i.e. with no pain or with stable pain at baseline).
At the cut-off date, pain progression or death had occurred in 507 participants, 263 in the Placebo group and 244 in the Aflibercept group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Progression-free Survival Time</title>
          <description>Pain progression was defined as either ≥1-point increase in Present Pain Intensity (PPI) score or ≥25% increase in Analgesics Score (AS) confirmed at least 3 weeks later, or requirement for palliative radiotherapy. PPI scale is a self-report 0-5 scale to assess pain intensity - a score 0 reflects no pain, a score 5 reflects excruciating pain. AS is a scoring method to assess analgesics consumption. Each analgesic is scored 1 or 4 depending on the analgesic type and dose. AS is the sum of the analgesic scores.
Pain progression-free survival (PFS) time was measured as the time from the date of randomization up to the date of first pain progression or death due to any cause, whichever occurred first.
The median pain-PFS and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of event, the participant was censored at the the date of last assessment without evidence of pain progression or the study cut-off date, whichever was earlier.</description>
          <population>The analysis was performed on the ITT population evaluable for pain progression (i.e. with no pain or with stable pain at baseline).
At the cut-off date, pain progression or death had occurred in 507 participants, 263 in the Placebo group and 244 in the Aflibercept group.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.72" lower_limit="8.509" upper_limit="11.499"/>
                    <measurement group_id="O2" value="9.20" lower_limit="8.181" upper_limit="10.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Response Rate</title>
        <description>Pain response was defined as either a ≥2-point decrease from baseline in Present Pain Intensity (PPI) score without increase in Analgesics Score (AS), or a ≥50% decrease from baseline in AS without increase in the PPI score confirmed at least 3 weeks later. Increases in PPI or AS during the first 12 weeks were ignored in determining pain response.</description>
        <time_frame>Before randomization (baseline) then every 3 weeks up to pain progression or the cut-off date, whichever occurred first</time_frame>
        <population>The analysis was performed in the ITT population evaluable for pain response (i.e. stable analgesia at baseline and, baseline PPI ≥2 and/or baseline AS ≥10 points).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Response Rate</title>
          <description>Pain response was defined as either a ≥2-point decrease from baseline in Present Pain Intensity (PPI) score without increase in Analgesics Score (AS), or a ≥50% decrease from baseline in AS without increase in the PPI score confirmed at least 3 weeks later. Increases in PPI or AS during the first 12 weeks were ignored in determining pain response.</description>
          <population>The analysis was performed in the ITT population evaluable for pain response (i.e. stable analgesia at baseline and, baseline PPI ≥2 and/or baseline AS ≥10 points).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" lower_limit="34.3" upper_limit="58.2"/>
                    <measurement group_id="O2" value="35.8" lower_limit="24.3" upper_limit="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life</title>
        <description>Functional Assessment of Cancer Therapy-Prostate (FACT-P) is a 39-item participant questionnaire that measures the concerns of patients with prostate cancer. It consists of 5 subscales assessing physical well-being, social/family well-being, emotional well-being, functional well-being, and prostate-specific concerns.
FACT-P total score is the sum of the 5 subscores. It ranges from 0 to 156 with higher score indicating better quality of life.</description>
        <time_frame>Before randomization (baseline) then every 3 weeks until disease progression or administration of further antitumor therapy, whichever came first</time_frame>
        <population>The analysis was performed on the ITT population evaluable for Health related quality of life (i.e. with baseline and at least one post-baseline evaluable FACT-P questionnaire).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life</title>
          <description>Functional Assessment of Cancer Therapy-Prostate (FACT-P) is a 39-item participant questionnaire that measures the concerns of patients with prostate cancer. It consists of 5 subscales assessing physical well-being, social/family well-being, emotional well-being, functional well-being, and prostate-specific concerns.
FACT-P total score is the sum of the 5 subscores. It ranges from 0 to 156 with higher score indicating better quality of life.</description>
          <population>The analysis was performed on the ITT population evaluable for Health related quality of life (i.e. with baseline and at least one post-baseline evaluable FACT-P questionnaire).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="574"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at cycle 1 (n =493, 461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="12.73"/>
                    <measurement group_id="O2" value="1.30" spread="15.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at cycle 2 (n =467, 437)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="14.50"/>
                    <measurement group_id="O2" value="-0.03" spread="17.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at cycle 6 (n =293, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="16.38"/>
                    <measurement group_id="O2" value="-1.00" spread="16.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at cycle 10 (n =158, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" spread="16.35"/>
                    <measurement group_id="O2" value="-1.60" spread="15.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety</title>
        <description>Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome or illness observed by the investigator or reported by the participant during the study.
AE were collected at regular intervals throughout the study then graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.3.0).</description>
        <time_frame>From first dose of study treatment (aflibercept/placebo or docetaxel whichever came first) to last dose of study treatment (aflibercept/placebo or docetaxel whichever came last) + 30 days</time_frame>
        <population>The analysis was performed on the safety population (i.e. all randomized and treated participants according to the treatment actually received). Six participants in the Placebo group who received at least one dose of aflibercept in error were considered in the Aflibercept group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety</title>
          <description>Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome or illness observed by the investigator or reported by the participant during the study.
AE were collected at regular intervals throughout the study then graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.3.0).</description>
          <population>The analysis was performed on the safety population (i.e. all randomized and treated participants according to the treatment actually received). Six participants in the Placebo group who received at least one dose of aflibercept in error were considered in the Aflibercept group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="585"/>
                    <measurement group_id="O2" value="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Grade 3-4 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- AE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>--- Related AE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- AE leading to permanent discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- AE leading to premature discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept</title>
        <description>Serum for detection of anti-drug antibodies (ADA) was collected in patients treated in selected centers only. Samples were analyzed using a titer-based, bridging immunoassay developed and validated to detect ADAs in human serum.
Samples with positive antibody levels were further analyzed using a validated, non-quantitative ligand binding assay to detect neutralizing antibodies Ab).
A participant was considered to have positive antibody levels if antibodies were detected above the quantification limits.</description>
        <time_frame>Pre-dose of cycle 1 (baseline), pre-dose of each every other cycle, then 30 and 90 days after the last administration of the study drug</time_frame>
        <population>The analysis was performed on the safety population evaluable for immunogenicity (i.e. exposed to aflibercept with serum samples evaluable for immunogenicity).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept</title>
          <description>Serum for detection of anti-drug antibodies (ADA) was collected in patients treated in selected centers only. Samples were analyzed using a titer-based, bridging immunoassay developed and validated to detect ADAs in human serum.
Samples with positive antibody levels were further analyzed using a validated, non-quantitative ligand binding assay to detect neutralizing antibodies Ab).
A participant was considered to have positive antibody levels if antibodies were detected above the quantification limits.</description>
          <population>The analysis was performed on the safety population evaluable for immunogenicity (i.e. exposed to aflibercept with serum samples evaluable for immunogenicity).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At any time post-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Neutralizing Ab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Not neutralizing Ab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Neutralizing potential not evaluated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AE) were collected from signature of the informed consent form up to the last visit in the study.</time_frame>
      <desc>The analysis was performed on the safety population as described for Outcome measure 10 (i.e. according to the treatment actually received) and included all AE that developed or worsened from first dose of aflibercept/placebo or docetaxel whichever came first, to 30 days after last dose of aflibercept/placebo or docetaxel whichever came last.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo, 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
        </group>
        <group group_id="E2">
          <title>Aflibercept</title>
          <description>Aflibercept, 6 mg/kg 1 hour IV, immediately followed by docetaxel, 75 mg/m² 1 hour IV, every 3 weeks in combination with oral prednisone or prednisolone, 5 mg PO twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="331" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pigmentary glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Faecalith</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract mucosal discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Necrotising colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Omental infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pharyngoesophageal diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rectal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Peridiverticular abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Herpes oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>West nile viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Electrocardiogram t wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Electrocardiogram st-t segment abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Ureteric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="551" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="573" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="268" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="340" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="241" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="230" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="598"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days for abstracts) in advance of any submission to a journal, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pain response initially defined as a key secondary endpoint together with PSA response, time to occurence of SRE and PFS was finally considered as an exploratory endpoint in final statistical analysis plan.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-Us@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

